BR10A Phase III Prospective Randomized Study of Adjuvant Chemotherapy with Vinorelbine and Cisplatin in Completely Resected Non-Small Cell Lung Cancer with Companion Tumour Marker Evaluation
BR12A Phase III Study of Marimastat in Patients with Small Cell Lung Cancer Following a Response to First Line Chemotherapy
BR15A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy with ZD1839 or Placebo in Patients with Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer
BR15CThis Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer
BR17Phase III Study of Tomudex and Cisplatin versus Cisplatin in Malignant Pleural Mesothelioma
BR18A Phase II/III Double Blind Randomized Trial of BMS-275291 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy For the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
BR19A Phase III Prospective Randomized Double Blind Placebo Controlled Trial of the Epidermal Growth Factor Receptor Antagonist ZD1839 (IRESSA) in Completely Resected Stage 1B, II, and IIIA Non-Small Cell Lung Cancer
BR20A Phase II Study of ZD6474 or Placebo in Small Cell Lung Cancer Patients Who Have Complete or Partial Response to Induction Chemotherapy Plus Radiation Therapy
BR21A Randomized Placebo Controlled Study of OSI-774 (Tarceva) in Patients with Incurable Stage IIIB/IV Non-Small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
BR22A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB(T2N0), II(T1-2N1, T3N0) and Selected IIIA(T3N1) Non-Small Cell Lung Cancer.
BR22CThis Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer
BR23CThis Protocol is a Laboratory Companion for Southwest Oncology Group Coordinated Trials for Lung Cancer
BR24A Phase II/III Double Blind Randomized Trial of AZD2171 versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
BR26A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease
BR28Concurrent ONce-daily VErsus twice-daily RadioTherapy: A 2-arm randomised controlled trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer (SCLC) and good performance status
BR29A Double Blind Randomized Trial of Cediranib versus Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer
BR31A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
BR34A Randomized Trial of Durvalumab and Tremelimumab +/- Platinum Based Chemotherapy in Patients with Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
BR36A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Non-Small Cell Lung Cancer
Inventory
Show Tissue Samples
| Disease Site | Trial Code | Patients Accrued | Patients - Blocks | Patients - Slides | Patients - Blocks and/or Slides |
| LUNG | BR10 | 532 | 451 | 454 | 471 |
| LUNG | BR12 | 555 | 54 | 4 | 58 |
| LUNG | BR15 | 56 | 10 | 2 | 12 |
| LUNG | BR15C | 47 | 3 | 3 | 6 |
| LUNG | BR17 | 20 | 1 | 1 | 2 |
| LUNG | BR18 | 774 | 165 | 236 | 262 |
| LUNG | BR19 | 503 | 376 | 414 | 425 |
| LUNG | BR20 | 107 | 53 | 7 | 55 |
| LUNG | BR21 | 731 | 270 | 432 | 438 |
| LUNG | BR22 | 6 | 0 | 1 | 1 |
| LUNG | BR22C | 5 | 0 | 3 | 3 |
| LUNG | BR23C | 8 | 0 | 2 | 2 |
| LUNG | BR24 | 296 | 53 | 118 | 145 |
| LUNG | BR26 | 720 | 601 | 672 | 690 |
| LUNG | BR28 | 41 | 1 | 1 | 1 |
| LUNG | BR29 | 306 | 101 | 79 | 159 |
| LUNG | BR31 | 1916 | 1365 | 116 | 1371 |
| LUNG | BR34 | 301 | 163 | 282 | 295 |
| LUNG | BR36 | 50 | 19 | 0 | 19 |
(Core size is 0.6 mm)
Show
Fluid Samples| Disease Site | Trial Code | Patients Accrued | TMA Blocks | Patients on TMA Blocks |
| LUNG | BR10 | 532 | 3 | 331 |
| LUNG | BR12 | 555 | 0 | 0 |
| LUNG | BR15 | 56 | 0 | 0 |
| LUNG | BR15C | 47 | 0 | 0 |
| LUNG | BR17 | 20 | 0 | 0 |
| LUNG | BR18 | 774 | 2 | 60 |
| LUNG | BR19 | 503 | 9 | 342 |
| LUNG | BR20 | 107 | 1 | 1 |
| LUNG | BR21 | 731 | 0 | 0 |
| LUNG | BR22 | 6 | 0 | 0 |
| LUNG | BR22C | 5 | 0 | 0 |
| LUNG | BR23C | 8 | 0 | 0 |
| LUNG | BR24 | 296 | 0 | 0 |
| LUNG | BR26 | 720 | 2 | 52 |
| LUNG | BR28 | 41 | 1 | 1 |
| LUNG | BR29 | 306 | 1 | 9 |
| LUNG | BR31 | 1916 | 1 | 32 |
| LUNG | BR34 | 301 | 1 | 6 |
| LUNG | BR36 | 50 | 0 | 0 |
| Disease Site | Trial Code | Patients Accrued | Patients - Whole Blood | Patients - Cellular Component of Blood | Patients - DNA extracted from Blood | Patients - RNA extracted from Blood | Patients - Plasma | Patients - Serum | Patients - Urine | Patients - Buccal |
| LUNG | BR10 | 532 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| LUNG | BR12 | 555 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR15 | 56 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR15C | 47 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR17 | 20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR18 | 774 | 0 | 0 | 0 | 0 | 20 | 439 | 0 | 0 |
| LUNG | BR19 | 503 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR20 | 107 | 0 | 0 | 0 | 1 | 99 | 0 | 93 | 0 |
| LUNG | BR21 | 731 | 0 | 0 | 0 | 0 | 728 | 1 | 0 | 0 |
| LUNG | BR22 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR22C | 5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR23C | 8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| LUNG | BR24 | 296 | 234 | 0 | 234 | 235 | 249 | 254 | 0 | 0 |
| LUNG | BR26 | 720 | 706 | 0 | 2 | 0 | 710 | 710 | 0 | 0 |
| LUNG | BR28 | 41 | 0 | 0 | 0 | 0 | 4 | 3 | 0 | 0 |
| LUNG | BR29 | 306 | 55 | 0 | 15 | 15 | 58 | 57 | 0 | 0 |
| LUNG | BR31 | 1916 | 991 | 0 | 0 | 0 | 877 | 993 | 0 | 0 |
| LUNG | BR34 | 301 | 299 | 0 | 0 | 0 | 299 | 298 | 0 | 0 |
| LUNG | BR36 | 50 | 0 | 0 | 0 | 0 | 50 | 0 | 0 | 0 |